eXoZymes achieves 100× scale-up of NCT production with >99% feedstock conversion

EXOZYMES INC.

Scaled NCT production 100-fold using proprietary exozyme cell-free platform, achieving >99% conversion from feedstock to product.
Batch executed under partner-operated conditions by Cayman Chemical, demonstrating process robustness and transferability.
CEO Michael Heltzen calls milestone an inflection point for cell-free enzyme-driven biomanufacturing.
Additional technical details and NCT extraction results expected in early 2026 after downstream analysis.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.